Pasar al contenido principal

CONTROL DE LA PROGRESION TUMORAL Y SU RESPUESTA INMUNE MEDIANTE EL REMODELAMIENTO DE LA MATRIZ EXTRACELULAR: INTEGRACION PARA UNA MEDICINA DE PRECISION

PID2019-104416RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD, M.P.

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

VCAN is essential for ERK5-driven tumorigenesis in soft tissue sarcoma

  • Jiménez-Suárez, Jaime
  • Cimas, Francisco J.
  • Paricio, José Joaquín
  • Belandia, Borja
  • Berrouayel, Yosra
  • Arconada-Luque, Elena
  • Matilla-Almazán, Sofía
  • Soffientini, Cesare
  • Percio, Stefano
  • Redondo-García, Silvia
  • García-Flores, Natalia
  • Garnés-García, Cristina
  • Fernández-Aroca, Pablo
  • Martínez-Gómez, Juan Jesús
  • Fernández-Aramburo, Antonio
  • Nam-Cha, Syong Hyun
  • Rovida, Elisabetta
  • Pandiella, Atanasio
  • Esparís-Ogando, Azucena
  • Pasquali, Sandro
  • Rodríguez Manzaneque, Juan Carlos
  • Peso, Luis del
  • Ruiz-Hidalgo, María J.
  • Sánchez-Prieto, Ricardo
The ERK5 signaling pathway has recently emerged as a critical regulator of soft tissue sarcoma (STS) biology, contributing to tumor initiation, progression, and maintenance. In this study, we identify VCAN, a chondroitin sulfate proteoglycan, as a novel transcriptional target of ERK5 and a central mediator of ERK5-related oncogenesis. Through a combination of genetic (silencing, overexpression) and pharmacological approaches, applied in both a chemically induced murine sarcoma model and several human STS cell lines, we demonstrate that ERK5 positively regulates VCAN expression. Functionally, VCAN silencing (by shRNAs) recapitulates the phenotypes of ERK5 silencing, including impaired migration, adhesion, proliferation, and tumorigenesis. Conversely, VCAN overexpression rescues these effects, confirming its essential role in ERK5-mediated oncogenesis. Furthermore, transcriptomic profiling reveals that VCAN accounts for a substantial portion of ERK5-regulated gene expression program. Analyses of human STS patient samples reveal significantly elevated mRNA levels of both VCAN and ERK5 compared to normal tissues. Notably, a strong correlation between VCAN and ERK5 expression, both at mRNA and protein levels, emerged in biopsies from leiomyosarcomas and undifferentiated pleomorphic sarcomas. Together, these findings uncover VCAN as a key effector in ERK5-driven tumorigenesis and highlight the ERK5/VCAN signaling axis as a promising therapeutic target in soft tissue sarcomas., Agencia Estatal de Investigación, PID2021-122222OB-I00, PID2019-104416RB-I00, PID2020-115605RB-I00 Junta de comunidades de Castilla La Mancha, SBPLY/23/180225/000007. Instituto de Salud Carlos III, https://ror.org/00ca2c886, PI19/00840 Universidad de Castilla La Mancha, 2022-GRIN-34150, No